INTRODUCTION
Levetiracetam (KEPPRA TM ) is a novel antiepileptic drug (AED) that has recently been released as an adjunctive therapy for partial epilepsy (Ben-Menachem and Falter 2000; Betts et al. 2000; Cereghino et al. 2000; Shorvon et al. 2000) . It is a derivative of pyrrolidine acetamide, which has a chemical structure similar to piracetam and is therefore unrelated to other currently available antiepileptics. Although the mechanism of action of levetiracetam has not been fully elucidated, it does not appear to involve any conventional modulation of the main known mechanisms relevant for the action of classical AEDs, i.e. direct increase of brain GABA levels (either through activation of GABA A receptors or through inhibition of GABA transporters or GABA transaminase), inhibition of voltagegated Na + -channels, or inhibition of low-voltage-gated (T-type) Ca 2+ -currents (Klitgaard 2001; Zona et al. 2001) . In contrast, it has recently been reported that levetiracetam reduces high-voltage-activated Ca 2+ -currents (Niespodziany et al. 2000) and reverses inhibition of GABA and glycine-gated currents induced by negative allosteric modulators (Rigo et al. 2000) . These effects probably contribute to the antiepileptic action of levetiracetam and may derive from an interaction of the drug with a brain-specific binding site (Noyer et al. 1995) . Sleep, epilepsy and the effects of AEDs are intimately related and are a frequent and real concern for patients, a fact reflected by findings that patients with epilepsy have more complaints about sleep disruption than normal controls (Hoeppner et al. 1984 ). The precise nature of this relationship has, however, not been resolved. The effects of sleep on epilepsy and epilepsy on sleep are complex. It is well known that sleep facilitates clinical and subclinical seizure activity in both partial and generalized epilepsies (Baldy-Moulinier 1982) . It is also possible that epileptic activity might itself disrupt the normal organization of sleep and cause sleep disruption. Partial epilepsy has effects on both sleep continuity [the number of awakenings is increased, total sleep time (TST) is decreased and sleep onset latency is increased] and sleep architecture [slow wave sleep (SWS) and rapid eye movement (REM) sleep are both reduced] (Binnie 1993) .
Establishing the effects of antiepileptic medication on sleep is similarly problematic and is confounded by the fact that the available literature is often difficult to interpret because the influence of the underlying epilepsy and the AED are not clearly differentiated. In volunteers, carbamazepine tends to have a unidirectional effect on sleep continuity with sleep onset latency and the number of awakenings being decreased (Yang et al. 1989) . The effects on sleep architecture are less clear cut -SWS is increased in most studies but the effects on REM sleep are equivocal. One study reported no change in percentage of REM sleep (Gann et al. 1994 ) whereas another reported a slight decrease (Yang et al. 1989) .
Two different approaches have been adopted to determine the effects of carbamazepine in epileptic patients. Two studies used a cross-sectional approach and looked at the sleep of epileptic patients on stable drug treatment at a point in time (Drake et al. 1990; Manni et al. 1990) . One found that sleep continuity was reduced (time awake after sleep onset, number of awakenings and shifts to a lighter stage of sleep were all increased) and REM latency was increased in patients on carbamzaepine compared with healthy controls (Manni et al. 1990 ). The other found that patients on carbamazepine monotherapy had more awakenings, and decreased REM sleep and SWS compared with monotherapy with other AEDs (Drake et al. 1990) . Two groups have studied the longitudinal effects of carbamazepine on sleep in patients. One study examined patients' sleep before starting carbamazepine and again after 1 month of treatment. This showed a similar stabilizing effect to that seen in healthy volunteers, i.e. decreased time awake after sleep onset, and a reduced number of awakenings and stage shifts (Touchon et al. 1987) . Another recent study also reported the sleep effects before starting carbamazepine and after 1 month of treatment and in addition recorded effects after the first dose (Placidi et al. 2000a) . This showed that acute administration of carbamazepine increased the number of stage shifts, reduced REM sleep, and increased REM fragmentation but these changes were almost completely reversed after 1 month of treatment.
The effects of other AEDs, e.g. lamotrigine and gabapentin on sleep have also been examined in healthy volunteers. In these studies effects were reported before and after 3 months of treatment (Placidi et al. 2000b) . Lamotrigine increased REM sleep and decreased the number of phase shifts and the percentage of SWS. Gabapentin increased the percentage of REM sleep and reduced the number of awakenings and the percentage of stage 1 sleep. In patients with epilepsy, lamotrigine caused a similar effect on REM sleep and decrease in arousals and stage shifts (Foldvary et al. 2001; Placidi et al. 2000b) with no patients complaining of insomnia, which is interesting in the light of a retrospective case-record study by Sadler (1999) reporting 6% incidence of insomnia induced by lamotrigine that seems to contradict a report by Foldvary et al. 2001 .
The whole area of sleep, epilepsy and the effects of AED present quite a confused picture. It is, however, important to examine the sleep effects of antiepileptic medication particularly as patients are likely to be maintained on treatment for several years; and indeed regulatory authorities have become increasingly interested in the sleep effects of psychotropics drugs. This paper reflects this interest and reports on the effects of levetiracetam on objective and subjective sleep parameters in both healthy volunteers and patients with partial epilepsy on stable carbamazepine monotherapy.
METHOD
The studies in healthy volunteers and patients were of similar design and had the approval of the local hospitals' Ethics Committees. All subjects received expenses to reimburse them for their time spent in the studies. The volunteer study took place between 1993 and 1994 and the patient study between 1996 and 1997.
Subjects

Study 1 (healthy volunteers)
Healthy volunteers were recruited through advertising and 13 Caucasian men between the age of 31 and 45 (mean 38.1 years) were selected. They were medically and psychiatrically well, had a stable sleep-wake routine, were on no other medication, did not abuse alcohol or other drugs and had a stable and not excessive caffeine and smoking history.
Study 2 (patients)
Patients with a well-established diagnosis of partial onset epilepsy were recruited from local general practices over a period of 6 months. All were on a stable and chronic (>1 year) dose of carbamazepine monotherapy on which their seizures were well controlled. Patients were not selected for the presence of sleep problems and all had a stable sleep-wake routine. They were medically and psychiatrically well, did not have excessive caffeine, alcohol or drug consumption and had not taken any other psychoactive medication in the previous 1 month. The group consisted of six male and 11 female Caucasians aged between 20 and 66 (mean 38.8 years). All patients had partial epilepsy with the first seizure occurring between 2 years 8 months and 26 years prior to entry into the study. The focus of the epilepsy was in the temporal lobe in seven patients, in the parietal lobe in one and in the temporal and frontal lobes in one. In eight patients the site of the focus was unknown.
Study design
The studies were of a double-blind crossover design with random allocation of a single dose of two different treatment regimens (1000 mg of levetiracetam or placebo), which in the patient study was added on to patients' stable carbamazepine monotherapy. The half-life of levetiracetam is 6-8 h, which meant that the 7-day period between treatments allowed sufficient time for washout of the drug to avoid carry-over effects. The 1000 mg studied dose was chosen because this is the recommended dose (maintenance 1000-3000 mg daily) in clinical practice. Levetiracetam and matching placebo were packed by UCB SA Pharma (Braine l'Alleud, Belgium).
The study schedule (shown in Fig. 1 ) was identical for healthy volunteers and patients apart from the fact that the patients had an additional screening visit 4 weeks before the start of the study (V1). This consisted of a full medical history including a detailed description of the epileptic disorder, a physical examination, blood sampling (for full blood count, biochemistry, plasma carbamazepine levels and pregnancy test in women) and urine sampling (for benzodiazepine screen). There was then a baseline period of 4 weeks to ensure stability of carbamazepine intake and seizure control at the end of which patients were seen again (V2). At this stage (V2), volunteers had a full physical history and examination, blood (for full blood count and biochemistry) and urine sampling (for benzodiazepine screen).
One week after these visits volunteers and patients were allocated to treatment of a single dose of study medication (1000 mg of levetiracetam or placebo) according to a doubleblind crossover design. They took these on the evaluation visits (V3 and V4) which were separated by a washout period of 7 days. Prior to these visits subjects were telephoned to check that there had not been any significant adverse events or seizures within the last 48 h. If there had been no problems they were visited at home during that evening and prepared for the recording using silver ⁄ silver chloride stick-on electrodes placed according to the International 10-20 system and the recommendations of Rechtschaffen and Kales (1968) (R&K) for sleep recordings. In addition, four extra electroencephalogram (EEG) channels over the right and left temporal area were recorded in patients specifically to examine epileptiform discharges over the course of the night. All subjects were instructed to take the medication at 22.00 h, volunteers were instructed to go to bed at 23.00 h, and the patients at their usual time, and to set their alarm for the time agreed on at visit 2 (volunteers instructed 07.30 h). The following morning the investigator returned to remove the apparatus, collect the completed subjective sleep rating questionnaires [St Mary's Sleep Questionnaire (SMSQ)] (Leigh et al. 1988) and Leeds Sleep Evaluation Questionnaire (LSEQ) (Parrott and Hindmarch 1978) for that night, to check on the occurrence of any seizures or adverse events and to repeat blood sampling (for full blood count, biochemistry, plasma levetiracetam, plasma carbamazepine levels and pregnancy test in women -the latter two tests in patients only) and urine sampling (for benzodiazepine screen). A final visit (V5) was performed 2 weeks ± 5 days after the last treatment intake for safety reasons. This included a check for any seizures in patients particularly or adverse events, a physical examination, blood sampling (for full blood count, biochemistry, plasma carbamazepine level and pregnancy test in women -again these latter two tests in patients only) and urine sampling (for a benzodiazepine screen).
Scoring of sleep EEGs -objective measures
All cassette tapes were scored blind to treatment. They were replayed on the Oxford Medilog system and scored visually according to R&K criteria. Measures derived were: sleep onset time (defined here as the time from patient pressing event marker when they put out the lights and tried to sleep to beginning of the first continuous period of 2 min not classified as awake or stage 1 sleep), TST, sleep efficiency, total time spent awake after sleep onset, number of awakenings (of at least 15 s in length), number of shifts to stage 1 or waking, REM onset latency (time from sleep onset to beginning of first REM period), time spent in each stage of sleep.
In addition, in the patient group epileptiform discharges were quantified visually for the whole night.
Scoring of sleep questionnaires -subjective measures
The questionnaires used to measure subjective effects were the St Mary's Hospital Sleep Questionnaire (SMHSQ) and the Leeds Sleep Evaluation Questionnaire (LSEQ). The SMHSQ includes questions about sleep latency, depth of sleep, number of awakenings, duration of sleep, quality of sleep, morning clear-headedness and satisfaction with sleep which are assessed using simple direct questions, open questions, yes ⁄ no questions and questions with differently scaled answers. The LSEQ is a visual analog scale with representations scored on 100 mm lines and assesses the time to fall asleep (speed and ease of getting to sleep and drowsiness), quality of sleep (restfulness, periods of wakefulness), morning wakefulness (ease and rapidity of awakening), feeling on waking, alertness and balance and co-ordination on waking. These questionnaires were completed by the volunteers and patients on the mornings after each EEG recording at V3 and V4.
Statistical analysis
In the volunteer study three objective parameters were considered as the primary efficacy variables: the effects of levetiracetam on sleep onset latency, TST and the number of awakenings after sleep onset. The rest of the objective parameters and all of the subjective parameters were considered as secondary efficacy variables.
In the patient study (because the results of the volunteer study were already known), the effects of levetiracetam on the number of shifts to stage 1 or waking as measured by the EEG was chosen as the primary efficacy variable. The secondary variables were to evaluate the effect of levetiracetam on TST, efficiency of sleep, number of awakenings after sleep onset, time spent asleep after sleep onset and REM onset latency. The effect on other objective parameters and all of the subjective parameters were considered as the other efficacy variables.
All statistical tests were two-tailed and conducted at 5% significance level. Tests for normality were conducted on all continuous data which were transformed if appropriate. The objective and subjective parameters (after log-transformation if appropriate) were submitted to analysis of variance (anova) for a two-treatment two-period crossover design (tests on treatment effect, period effect and interaction treatment by period) (Hills and Armitage 1979; Kenward and Jones 1987; Senn 1993) . All categorical and non-normal continuous variables were analysed using the Wilcoxon rank-sum test on these three effects (Koch 1972) .
RESULTS
A total of 12 volunteers completed the study, 17 subjects completed the patient study but an EEG electrode broke during one recording in one patient which meant that complete data were only obtained in only 16 patients. His subjective measures were included in the analysis.
Objective polysomnographic data Table 1 summarizes the statistical results for the objective sleep parameters for the nights on levetiracetam and placebo.
In the healthy volunteer study no significant differences were detected between levetiracetam and placebo on the primary efficacy measures (TST, sleep onset latency and number of awakenings). The only significant findings were that on levetiracetam the total time spent in stage 2 sleep was significantly increased (35 min; 95% CI: 9-60 min), and that there was a significant increase of REM latency with levetiracetam (geometric means ratio placebo ⁄ levetiracetam of 0.63; 95% CI: 0.46-0.86). The finding of an increase in the total time spent in stage 2 sleep was replicated by the patient study (57 min; 95% CI: 36-83 min) with no significant differences being found on the primary efficacy measure of the number of stage shifts to stage 1 or waking (Fig. 2) . This study also found that there was a significant decrease in the time spent in stage 4 sleep (16 min; 95% CI: 2-31 min).
There was significant treatment · period interaction for the total time spent in stage 1 sleep in the patient study (but no significant effects of period or treatment) for which there is no clear explanation. Table 2 summarizes the continuous subjective measures (scores in millimetres from LSEQ, and sleep latency and duration of sleep in minutes from SMHSQ) from both studies.
Subjective measures from sleep questionnaires
In the volunteer and patient studies, the significantly different subjective LSEQ measures was the item for the number of periods of wakefulness which were fewer with levetiracetam (Table 2 ). In addition, in the patient study subjects reported feeling that their sleep was more restful. Volunteers reported that awakening was harder and took longer with levetiracetam and patients reported feeling less alert on waking. There was a treatment · period interaction effect for the item feeling alert in the morning. On scrutiny of the data it was seen that subjects receiving levetiracetam first (in period 1) had a smaller drug ⁄ placebo difference than those receiving levetiracetam second. This difference was because of to different ÔalertnessÕ scores on placebo which were lower in subjects who had levetiracetam second. The scores on levetiracetam for both periods were similar on both occasions being around the 50 mm mark -indicating no change from normal. Table 3 summarizes the categorical subjective measures from the SMHSQ for both studies.
In the volunteer study, no items from the SMHSQ were significantly different between the two treatments. In the patient study, the only significantly difference was the item for the number of awakenings (there being less awakenings with levetiracetam). There was also a treatment · period interaction for the items depth and quality of sleep. In both of these the patients who had levetiracetam first tended to score lower for the drug than if they had levetiracetam second. The scores for levetiracetam were higher than placebo on both occasions. A possible explanation could be the novelty of the drug -if subjects had it first they had nothing to compare it with.
In summary, on levetiracetam healthy volunteers and patients had a significant increase in the total time spent in stage 2 sleep, an increase in REM latency (volunteers only) and a decrease in stage 4 sleep (patients only). Subjectively, on levetiracetam they reported their sleep to be of better quality with fewer awakenings and patients also reported feeling that their sleep was more restful. Volunteers and patients both reported feeling less alert on waking or in the morning when on levetiracetam.
There was a positive correlation between most of the objective and subjective parameters measured in both studies. Interestingly, however, in both studies there was a discrepancy between the objective and subjective parameters with respect to the number of shifts to stage 1 or waking which were subjectively rated as less on levetiracetam (on the LSEQ in both studies and by the SMHSQ in the patient study) but objectively was found to be not different from placebo. It has been established that an awakening only becomes a conscious event after it has lasted for more than 120 s. Additional analyses were therefore performed in the patient study in order to test the hypothesis that patients had a decrease in longer awakenings on levetiracetam, while the total time spent awake remained equal. Data was grouped according to whether or not the awakening was greater or less than 120 s (denoted as For the LSEQ the lower the value the more like the description in table. Statistically significant differences between treatment groups at 5% level are indicated in bold. *Significant treatment · period interaction.
ÔlongÕ or ÔshortÕ groups, respectively). Initially, a frequency distribution of the average length of each awakening for each patient across treatments was produced. From this it was seen that patients taking placebo had average waking times of 25 s longer than those taking levetiracetam. It was observed, however, that the data were variable and no firm conclusions could be drawn from this descriptive analysis alone. It nevertheless gave an indication of possible differences between the two treatment groups. Analyses were performed on five further variables (total time spent awake, average time of short awakenings, average time of long awakenings, percentage of awakenings less than 120 s, percentage of awakenings greater than 120 s) but none of these proved to be significant. However, the fact that the average duration of waking times seems a little higher on placebo than levetiracetam may be a possible cause as to why periods of wakefulness and restfulness (as measured by the LSEQ) showed a significant difference in favour of levetiracetam. It may be possible that patients on placebo experienced more periods of being awake for longer than 120 s than when they were on levetiracetam.
Effects of carbamazepine on sleep in patients with partial epilepsy
The results of the placebo effects in the patient study give us some information of the effects of carbamazepine on sleep. Objectively, the striking finding was the increase in SWS compared with healthy volunteers (Fig. 3) . There was also a decrease in stage 2 sleep and an increase in REM latency. Subjectively, there were no major differences from healthy volunteers.
Epileptiform activity in the patient group
Patients' epileptiform activity was analysed descriptively. Patients were divided into two groups according to whether or not they had interictal paroxysmal activity (IPA) in the sleep EEG. This showed that the group with IPA had slightly worse sleep continuity measures than the group without IPA. When the discharge activity in the patient study was examined it was found that six patients had excess theta activity in the waking EEG and one other had excess delta activity. Ten patients had poorly formed sleep features, particularly sleep spindles and in two patients sleep spindles were virtually absent. Eight of the 17 patients had interictal epileptiform discharges, usually consisting of bursts of mixed slower waves with interspersed spikes or sharp waves, sometimes unilateral but often bilateral with possible unilateral initiation. In all but one patient these were of less than 5 s duration and in a single patient they lasted 12-30 s and were accompanied by movement and electromyogram artefact. Most discharges occurred during stages 1 and 2 sleep, and in two patients they occurred also during REM sleep.
The effect of levetiracetam on the discharge activity is shown in Table 4 . The numbers are very small but illustrate the fact that levetiracetam reduced bilateral discharges and had no effect on unilateral discharges. It also had more effect in patients with more activity, i.e. >1 min than those with less activity.
There were no serious adverse events in either of the studies and the most frequently reported problems were those previously reported with levetiracetam, i.e. drowsiness, dizziness and unsteadiness. There were also no differences in the clinical blood laboratory tests results during the studies between levetiracetam and placebo. 
DISCUSSION
This study was designed to examine the effects of levetiracetam on sleep in healthy volunteers and patients with partial epilepsy, the indication for which levetiracetam has been initially approved. It did, however, also allow us to make some comments on the effects of carbamazepine on sleep in patients, on the relationship between epileptiform activity and sleep and how this was changed by levetiracetam.
Effects of levetiracetam on sleep
The results from the two studies show considerable similarities. In both, levetiracetam produced an increase in the time spent in stage 2 sleep, which in the patient study was accompanied by a decrease in the time spent in stage 4 sleep. These findings are interesting because stage 2 sleep is increased by many different types of drugs, particularly benzodiazepines, barbiturates and some antidepressants, but with these it is accompanied by changes in sleep continuity (increase in TST and a decrease in sleep onset latency, time spent awake in bed and number of episodes of stage 1 or awakening). The finding that levetiracetam does not have significant effects on these measures means that it is, therefore, different from these hypnotic drugs. The decrease in stage 4 sleep has been described with high doses of benzodiazepines and barbiturates but again this is usually accompanied by changes in sleep continuity which were not seen here. Increases in REM latency as the one observed in the volunteer study have also been reported with antidepressant and hypnotic drugs, but this is usually accompanied by an overall reduction in REM time, which was not seen in this study. There was also no increase in SWS in the first half of the night to account for the delayed REM (increased SWS in the first cycle and decreased latency to SWS have been described after barbiturates and alcohol but were not seen here). The changes in subjective measures reported in both studies after administration of levetiracetam were also quite similar. Subjects reported that their sleep was of a better quality with fewer awakenings and patients also reported that their sleep was more restful. They also both reported that they felt less alert on waking or in the morning. Both groups, therefore, reported a decrease in awakenings after levetiracetam despite the finding from the EEG of no change in the actual number of awakenings. It may be concluded from this that levetiracetam is affecting sleep perception, but not objective sleep measures of sleep continuity. When we explored this further examining the duration of the awakenings there was a suggestion that patients on levetiracetam had shorter wakes (<120 s) than when they were on placebo although this did not reach clinical significance. The trend may, however, explain the discrepancy between the objective and subjective findings.
The results of this single-dose study may not be applicable to people with chronic epilepsy receiving long-term medication with levetiracetam.
Effects of carbamazepine on sleep of patients with partial epilepsy
The results from the patient study during placebo treatment also give us some information about the sleep of patients with partial epilepsy on stable carbamazepine monotherapy. This shows that patients on carbamazepine had a marked increase in SWS, a decrease in stage 2 sleep and an increase in REM latency compared with healthy volunteers. These results have some similarities with other published studies, the increase in SWS being reported with carbamazepine in healthy volunteers (Gann et al. 1994; Yang et al. 1989 ) and the increase in REM latency being reported by some studies in patients (Manni et al. 1990 ). The decrease in stage 2 sleep has not been previously reported. Subjectively, there were no obvious differences between healthy volunteers and patients on carbamazepine.
Effects of epileptiform activity
The fact that one arm of this study was performed in patients with abnormal epileptiform activity also provided some information about the consequences of this on sleep and the effect of levetiracetam on the underlying condition. The finding that the group of patients with IPA had worse sleep continuity also fits with some of the previous literature which suggests that increasing severity of epilepsy or increasing frequency of activity is associated with increasing sleep disturbance. Although the numbers are very small, the finding that levetiracetam reduces bilateral activity particularly in patients with more discharges is interesting. 
